Special Charges (d) - - 0.58 0.58
Adjusted Diluted Earnings
Per Share $1.57 $1.65 $0.96 $0.97 64% 70%
(d) Diluted earnings per share for fiscal year 2008 includes after-tax
charges of $2.0 million, or $0.16 per share, for the acceleration of
stock awards, approximately $214,000, or $0.02 per share, of charges
related to the discontinuation of the Company's embolic protection
platform, both of which were incurred during the first quarter of
fiscal 2008, and an estimated $5.1 million, or $0.41 per share,
related to the sale of the Company's endovascular business during the
fourth quarter of fiscal year 2008.
Note: To supplement our consolidated financial statements presented in accordance with GAAP, Kensey Nash Corporation uses non-GAAP measures of adjusted earnings per share, which are adjusted from our GAAP results to exclude certain expenses. These non-GAAP adjustments are provided to enhance the user's overall understanding of our historical and current financial performance and our prospects for the future. We believe the non-GAAP results provide useful information to both management and investors by excluding certain expenses that we believe are not indicative of our core operating results.
These non-GAAP measures will provide investors and management with an alternative method for assessing Kensey Nash's operating results in a manner consistent with future presentation. Further, these non-GAAP results are one of the primary indicators management uses for planning and forecasting in future periods. The presentation of this additional information should not be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
|SOURCE Kensey Nash Corporation|
Copyright©2008 PR Newswire.
All rights reserved